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MEASURING QUALITY OF LIFE WITH EQ-5D IN AN
AUSTRIAN OUTPATIENT CLINIC FOR PATIENTS WITH
DIABETES MELLITUS
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Semlitsch B2, Haas H2, Pieber TR1
1Joanneum Research, Graz, Styria, Austria; 2University Hospital Graz,
Graz, Styria, Austria
OBJECTIVE: EQ-5D has become a standardised instrument for
measuring quality of life (QoL). Actually there is no data avail-
able for Austrian diabetic patients. We surveyed QoL of diabetic
patients in an outpatient clinic in Styria and applied EQ-5D the
ﬁrst time in such a setting. Aim of the survey was to gain insights
the overall QoL in this patient group and testing the practical-
ity and understandability of EQ-5D in an Austrian outpatient
clinic setting. METHODS: EQ-5D and EQ-VAS were used to
measure QoL at a random sample visiting the outpatient clinic
within the 12 weeks of survey. The form was handed out in hard-
copy to n = 103 patients (7% in-patient, 93% out-patient) during
the waiting time for consultation. All 103 patients responded 
to the form. RESULTS: Rate of completed questions was high,
94% responded to mobility, 95% to personal care, 93% to usual
activities, 92% to anxiety/depression and 86% to VAS-Score. 
It turned out that VAS was the most difﬁcult question for the
patients to assign. 24% of patients had Diabetes mellitus (DM)
1 (39% women) with a mean age of 43 (SD ± 13) years, 75%
of patients with DM2 (53% women) were mean 65 (SD ± 12)
years old, in 1% of patients DM type was missing. Mean QoL
measured with VAS-Score was in patients with DM1 82 (±15),
Median 83 (80–90) and mean QoL 62 (±21), Median 63 (50–80)
for patients with DM2. Patients with DM1 had a signiﬁcantly
higher QoL (p < 0.001, Wilcoxon test) than patients with DM2.
CONCLUSION: The survey showed that EQ-5D can be easily
integrated in the operating processes of an outpatient clinic and
all patients were willing to ﬁll out the EQ-5D. In a next step EQ-
5D will be linked to medical data to gain more information
about EQ-5D and medical situation.
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AN ASSESSMENT OF THE LONG-TERM OUTCOME FOR
LIRAGLUTIDE+METFORMIN VERSUS METFORMIN AND
VERSUS METFORMIN+GLIMEPIRIDE IN TYPE-2 PATIENTS
WITH INADE-QUATE GLYCAEMIC CONTROL
Hammer M1,Valentine WJ2,Wittrup-Jensen KU1, Palmer AJ2
1Novo Nordisk A/S, Bagsvaerd, Denmark; 2CORE Center for
Outcomes Research, Binningen, Switzerland
OBJECTIVES: Poor glycemic control is associated with
increased risk of complications in Type-2 diabetes. A recent clin-
ical trial demonstrated that Liraglu-tide+Metformin (Lira/Met)
versus Metformin (Met) signiﬁcantly improved HbA1c (0.82%-
points lower after 5 weeks). In the same study Lira/Met versus
Met-formin+Glimipiride (Met/SU) signiﬁcantly improved weight
by approximately 3%-points. The objective is to link these short-
term outcomes to long-term complication rates. METHODS:
A validated model which project long-term complications,
improvements in Life-Years Gained (LYG) and Quality-Adjusted
Life Years (QALY). Standard Markov modeling was used to
describe incidence and progression of com-placations (cardio-
vascular disease, neuropathy, renal and eye disease). Probabili-
ties of complications and HbA1c-dependent adjustments were
derived from the DCCT, UKPDS, and WESDR studies. Clinical
input was taken from a 5 week double-blind, double-dummy,
randomized, parallel-group, dose titration study with an open la-
belled OHA arm phase II trial in Type-2 patients. Outcomes were
estimated at 3% per annum and beneﬁts were projected over
patients’ lifetime. RESULTS: Improved glycemic control and
weight proﬁle with Lira/Met versus Met and versus Met/SU, re-
specify, led to decreased diabetes-related complications, with a
subsequent in-crease in LYG of 0.33 and 0.29 QALYs compared
to Met and 0.18 LYG and 0.14 QALY compared to Met/SU.
CONCLUSION: Improvements in glycemic control and weight
led to long-term improvement of both LYG and QALY when
comparing Lira/Met treat-mint to Met and Met/SU treatment.
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TREATMENT SATISFACTION AND QUALITY OF LIFE WITH
AN EARLY INSULINIZATION STRATEGY WITH INSULIN
GLARGINE COMPARED TO AN ADJUSTED ORAL THERAPY IN
THE MANAGEMENT OF TYPE-2 DIABETES:THE CANADIAN
INSIGHT STUDY
Houlden R1, Harris S2,Yale JF3, Sauriol L4, Dempsey E5,
Gerstein HC6
1Queen’s University, Kingston, ON, Canada; 2Thames Valley Family
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Canada; 5Aventis Pharma Canada, Laval, AB, Canada; 6McMaster
University, Hamilton, ON, Canada
OBJECTIVES: The objective of this study was to assess the
impact of early basal insulinisation with Lantus in people with
type-2 diabetes failing to reach optimal glucose control with oral
therapy. METHODS: The Canadian INSIGHT study was a 24-
week trial of patients with Type-2 diabetes randomized to receive
insulin glargine added to current therapy, or adjusted oral
therapy. Nineteen endocrinologists or experts selected 34 family
physicians for a mentor/preceptor relationship, facilitating
insulin initiation. Treatment satisfaction (TS) and quality of life
(QoL) were also assessed for all 405 patients randomized to
either the glargine (206) or the adjusted oral therapy arm (199).
TS and QoL were assessed using the Diabetes Treatment Satis-
faction Questionnaire (DTSQ) and the Audit of Diabetes Depen-
dant QoL (ADDQoL) questionnaire. Both self-administered
questionnaires were administered at baseline, week 12 and 24.
A total of 376 and 364 patients completed the DTSQ and the
ADDQoL questionnaires, respectively. RESULTS: At baseline,
TS and QoL were similar in both treatment arms. A1c reduction
was greater with glargine (p < 0.001). The total DTSQ score and
the TS items (items 1, 4, to 8) improved from baseline in both
treatment arms (p < 0.001); however, there was signiﬁcantly
more satisfaction with treatment with insulin glargine for the
DTSQ total score (p = 0.024) and the TS items (p = 0.011). Per-
ceived frequency of hyperglycaemia and hypoglycaemia (DTSQ
items 2 and 3) were signiﬁcantly (P < 0.05) lower at week 12
and 24 for all subjects with no distinguishable differences for the
two treatment arms at week 24. Only perceived hyperglycemia
was signiﬁcantly (P < 0.01) lower for glargine at week 12. Finally,
overall QoL improved in both groups (p < 0.001); however,
glargine had a greater impact at week 12 (p = 0.025) and end-
point (p = 0.024). CONCLUSIONS: Improving glucose control
with glargine had a positive impact on TS and general QoL
without complaints related to hypoglycemia.
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OBJECTIVE: Diabetic peripheral neuropathy (DPN) is a debili-
tating complication of diabetes and causes sensory symptoms
that impact health and functionality. The purpose of this study
was to test the hypothesis that there was a direct association
between the symptoms associated with DPN (SDPN), as mea-
sured by a new instrument the Neuropathy Total Symptom Score
(NTSS-6 [self administered]), and health-related utility as mea-
sured by the EQ5Dindex. The NTSS-6 provides a score of 0 to 3.66
in each of six domains. The score (range 0 to 21.96) is simply
summed with zero meaning no symptoms. METHODS: A postal
survey using various instruments including the NTSS-6 and the
EQ5D was mailed to subjects identiﬁed at random as having
either type-1 or Type-2 diabetes using the same methods as the
Health Outcomes Data Repository (HODaR). Univariate and
multivariate analysis were applied. This is a preliminary analy-
sis of the ﬁrst 604 returns. RESULTS: The mean age of respon-
dents was 64 years (IQR 55–73); 58% were male and the mean
duration of diabetes was 14 years (IQR 5–18). Of the 604
patients, 24% reported having no neuropathic symptoms. The
overall mean (SD) EQ5Dindex was 0.65 (0.33), and mean NTSS-
6 score 6.2 (median and IQR 4.33, 1.0–10.33). In univariate
analysis there was a direct association between the two instru-
ments (correlation coefﬁcient 0.57). Modeling the EQ5Dindex in
multiple linear regression analysis to account for confounding,
the NTSS-6 score was found to remain directly associated with
utility, whereby an increase of one unit on the NTSS-6 resulted
in as reduction in the EQ5Dindex of 0.029 units (p < 0.001). 
CONCLUSIONS: SDPN, as measured by the NTSS-6, were
directly associated with health-related utility. After accounting
for confounding factors, a unit change in the NTSS-6 was equiv-
alent to a change in utility that is considered to be clinically
meaningful.
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DEVELOPMENT OF A SCALE FOR DIABETIC PATIENT
PROFILING BASED ON PATIENT ATTITUDE TOWARDS
INSULIN
Arnould B1, Consoli S2, Martinez L3,Wong O4,Yomtov B5, Simon D6,
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Hospital, Paris, France; 3Private Practice, Bois D’arcy, France; 4Private
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OBJECTIVE: To develop self-report questionnaires for physician
use in the evaluation of diabetic patient reluctance to start or
step up insulin regimens. METHODS: An Advisory Committee
(AC) was set up. It consisted of 3 diabetes specialists/endocri-
nologists, 1 behavioural psychiatrist and 2 general practitioners.
Three patient focus groups were formed from a pool of 23 type-
1 and 2 diabetic patients. Interviewees were asked to list fears,
constraints and beneﬁts associated with insulinization, injection
and insulin regimen step-up. After analysis of the focus groups,
a list of detailed concepts and two test questionnaires were devel-
oped and independently validated by the AC with content valid-
ity being assessed on 16 type-1 and 2 diabetic patients. Patients
completed the questionnaires before being systematically asked
to comment on the questionnaire as a whole and more speciﬁ-
cally on each element of the questionnaire. Questionnaires were
then redrafted and tested on 16 other patients. After analysis of
patient tests, a revised questionnaire was produced and validated
by the AC. RESULTS: Eleven elements (Insulinization: symbolic,
fears, constraints, beneﬁts, product physical characteristics.
Injection: symbolic, fears, constraints, positive points. Insulin
regimen intensiﬁcation: symbolic, fears) and 31 detailed concepts
were identiﬁed using the patient focus groups. Each test ques-
tionnaire contained 22 items (20 relating to insulin regimen start
or insulin regimen step-up plus 2 relating to inhaled insulin).
After initial cognitive debrieﬁng, one item was added, taking
each questionnaire to 23 items and response choices were 
signiﬁcantly modiﬁed in both questionnaires by the AC. After
second cognitive debrieﬁng 2 items were excluded from both
questionnaires by the AC. The pilot questionnaires therefore
included 21 items. CONCLUSION: These pilot questionnaires
may help physicians to assess the hurdles faced by diabetic
patients in starting or stepping up insulin regimens. The ques-
tionnaires are now undergoing item reduction, scoring and 
validation in two case-report studies.
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DEVELOPMENT AND EVALUATION OF THE ASK ADHERENCE
BARRIER SURVEY IN PATIENTS WITH CHRONIC
CONDITIONS
Yu–Isenberg KS1, Espindle DM2, Skinner EP1,Weaver MB1,
Olson PS1, Hahn SR3
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OBJECTIVE: To develop and evaluate a self-report clinical and
research adherence barrier survey designed to screen for speciﬁc
barriers to adherence across a spectrum of chronic conditions.
METHODS: Item generation and domain structures were based
on literature and expert opinion. Interviews with 33 patients
with asthma, diabetes, and heart failure were used to develop 47
Likert-type items. These were tested on the Web with 605
patients with asthma, diabetes, and depression. Factor analysis
was performed to identify conceptually similar item groupings;
and item validity in relation to a self-reported measure of adher-
ence, the distribution of item responses, and factor structure
were studied to select ﬁnal survey items. RESULTS: Twenty items
were retained based on correlation with validity criteria and clin-
ical relevance in the following domains: Lifestyle, Attitudes and
Beliefs, Help from Others, Talking with Health care Team, and
Difﬁculty Taking Medicines. A post hoc cut point dichotomizing
responses into “present” and “absent” was selected for each
item. The Barrier Total Index (BTI), the number of “barrier-
present” items, had an observed range from 0 to 18, a mean of
4.2 (±3.4), and good reliability (Cronbach’s alpha = 0.77). The
validity of the BTI with a self-report of a missed dose of medi-
cine in the past week was excellent. Patients who “missed” had
a mean of 6 barriers vs. 2.6 for those who did not (p < 0.0001).
CONCLUSION: The ASK Adherence Barrier Survey appears 
to be a useful tool to identify barriers to adherence in chronic
diseases. The survey can facilitate discussion of adherence 
and identify opportunities to implement barrier-speciﬁc 
interventions.
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PERCEIVED HEALTH CARE INFORMATION ON DIABETES:
MEASUREMENT OF PATIENT SATISFACTION
Carmosino G1, Zerbini O1, Comarella L2, Morelli P2, Balestri M3,
Brioschi A3
1CROM Srl Contract Research Organisation Medical and
Pharmaceutical Projects,Verona, Italy; 2CROS NT Srl,Verona, Italy;
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Patient knowledge on own disease is recognised as key factor to
reach therapeutical goals. OBIECTIVE: To develop a question-
naire exploring patient preference on SBGM systems; to measure
patient satisfaction on medical information delivered by the hos-
pital health care personnel. METHODS: 454 NIDDM patients,
